Congenital CMV: Difference between revisions
From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | == Background == |
| + | |||
| + | * Infection with [[cytomegalovirus]] acquired in utero |
||
| + | * See also [[CMV in pregnancy]] |
||
| + | |||
| + | ===Epidemiology=== |
||
*Maternal seroconversion in about 2% of pregnancies |
*Maternal seroconversion in about 2% of pregnancies |
||
Revision as of 09:32, 2 August 2020
Background
- Infection with cytomegalovirus acquired in utero
- See also CMV in pregnancy
Epidemiology
- Maternal seroconversion in about 2% of pregnancies
- Higher in childcare workers
- Risk of transmission to fetus
- About 1 in 200 live births in US
- Primary infection: 30% risk of congenital CMV; higher risk later in pregnancy, but worse outcomes earlier
- Non-primary
- Reinfection: 5% risk
- Reactivation: 1% risk
Clinical Manifestations
- Mother may have had asymptomatic infection
- At birth
- Later
- Cognitive deficits (7%)
- Sensorineural hearing loss (20%)
Diagnosis
- In mom, IgM antibodies
- In baby, urine PCR within 2 weeks of birth
Management
- Treatment is indicated for symptomatic babies
- Brain
- Hearing
- Eye
- IV ganciclovir or PO valganciclovir, for 6 months
- Monitor CBC while on therapy
